Idorsia Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.63%

Idorsia Ltd (IDIA) has an Asset Resilience Ratio of 1.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read IDIA current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CHF7.39 Million
≈ $9.35 Million USD Cash + Short-term Investments

Total Assets

CHF454.57 Million
≈ $574.70 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Idorsia Ltd's Asset Resilience Ratio has changed over time. See Idorsia Ltd (IDIA) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Idorsia Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Idorsia Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF0.00 0%
Short-term Investments CHF7.39 Million 1.63%
Total Liquid Assets CHF7.39 Million 1.63%

Asset Resilience Insights

  • Limited Liquidity: Idorsia Ltd maintains only 1.63% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Idorsia Ltd Industry Peers by Asset Resilience Ratio

Compare Idorsia Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 36.07%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Biohaven Ltd.
NYSE:BHVN
Biotechnology 16.03%
Galapagos NV
F:GXEA
Biotechnology 86.45%
Beijing Hotgen Biotech Co Ltd
SHG:688068
Biotechnology 20.87%

Annual Asset Resilience Ratio for Idorsia Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Idorsia Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 3.55% CHF17.98 Million
≈ $22.73 Million
CHF505.89 Million
≈ $639.59 Million
+1.00pp
2023-12-31 2.55% CHF12.76 Million
≈ $16.14 Million
CHF500.00 Million
≈ $632.13 Million
-33.98pp
2022-12-31 36.53% CHF330.33 Million
≈ $417.62 Million
CHF904.18 Million
≈ $1.14 Billion
-26.64pp
2021-12-31 63.17% CHF936.77 Million
≈ $1.18 Billion
CHF1.48 Billion
≈ $1.87 Billion
-0.87pp
2020-12-31 64.04% CHF919.22 Million
≈ $1.16 Billion
CHF1.44 Billion
≈ $1.81 Billion
-9.96pp
2019-12-31 74.00% CHF743.07 Million
≈ $939.44 Million
CHF1.00 Billion
≈ $1.27 Billion
+8.34pp
2018-12-31 65.66% CHF923.67 Million
≈ $1.17 Billion
CHF1.41 Billion
≈ $1.78 Billion
+0.58pp
2017-12-31 65.08% CHF840.75 Million
≈ $1.06 Billion
CHF1.29 Billion
≈ $1.63 Billion
-14.47pp
2016-12-31 79.55% CHF727.98 Million
≈ $920.36 Million
CHF915.12 Million
≈ $1.16 Billion
--
pp = percentage points

About Idorsia Ltd

SW:IDIA Switzerland Biotechnology
Market Cap
$1.43 Billion
CHF1.13 Billion CHF
Market Cap Rank
#8742 Global
#121 in Switzerland
Share Price
CHF4.44
Change (1 day)
+1.32%
52-Week Range
CHF2.93 - CHF6.89
All Time High
CHF33.62
About

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more